A new PTP parameter as potential predictor of prostate cancer response to therapy.
The product coming from numerical values of blood testosterone and prolactin concentrations (both in ng/mL) was used in discriminating hormone dependent from hormonally refractory prostatic carcinoma. This parameter has been denoted as a PTP value and was tested clinically as potential predictor of prostate cancer response to therapy in 235 first presented patients. Numerical value of the PTP parameter below 10, if computed as described herein, indicates hormone insensitive prostate cancer which is treated initially with either chemohormonal or cytotoxic agents.
Tarle
M
M
Nuclear Medicine and Oncology Clinic, Clinical Hospital Dr. Mladen Stojanović, Croatia, Yugoslavia.
D000328:Adult; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000097:blood* / Q000628:therapy; D011379:Prognosis; D011388:Prolactin / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000628:therapy; D013739:Testosterone / Q000097:blood*
D013739:Testosterone; D011388:Prolactin